These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21541756)

  • 1. Fasciola hepatica: time-dependent disruption of spermatogenesis following in vivo treatment with triclabendazole.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Parasitol Res; 2011 Oct; 109(4):1035-43. PubMed ID: 21541756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent changes to the tegumental system and gastrodermis of adult Fasciola hepatica following treatment in vivo with triclabendazole in the sheep host.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Vet Parasitol; 2010 Dec; 174(3-4):218-27. PubMed ID: 20933333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Vet Parasitol; 2010 Sep; 172(3-4):238-48. PubMed ID: 20627418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of compound alpha treatment in vivo on egg production by the liver fluke, Fasciola hepatica.
    McConville M; Hanna RE; Brennan GP; Edgar HW; McConnell S; McCoy M; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2012 Jun; 187(1-2):183-95. PubMed ID: 22285009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasciola hepatica: disruption of spermatogenesis by the fasciolicide compound alpha.
    McConville M; Hanna RE; Brennan GP; McCoy M; Edgar HW; McConnell S; Castillo R; Hernández-Campos A; Fairweather I
    Parasitol Res; 2010 Jan; 106(2):311-23. PubMed ID: 19921260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of egg formation by Fasciola hepatica following treatment in vivo with triclabendazole in the sheep host.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Vet Parasitol; 2011 Apr; 177(1-2):79-89. PubMed ID: 21163580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early onset of changes to the reproductive system of Fasciola hepatica following in vivo treatment with triclabendazole.
    Hanna RE; Scarcella S; Solana H; McConnell S; Fairweather I
    Vet Parasitol; 2012 Mar; 184(2-4):341-7. PubMed ID: 21944196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole.
    Halferty L; Brennan GP; Hanna RE; Edgar HW; Meaney MM; McConville M; Trudgett A; Hoey L; Fairweather I
    Vet Parasitol; 2008 Aug; 155(1-2):49-58. PubMed ID: 18511199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthelmintic efficacy of triclabendazole against Fasciola hepatica in sheep.
    Turner K; Armour J; Richards RJ
    Vet Rec; 1984 Jan; 114(2):41-2. PubMed ID: 6719804
    [No Abstract]   [Full Text] [Related]  

  • 10. Fasciola hepatica: Histology of the testis in egg-producing adults of several laboratory-maintained isolates of flukes grown to maturity in cattle and sheep and in flukes from naturally infected hosts.
    Hanna RE; Edgar H; Moffett D; McConnell S; Fairweather I; Brennan GP; Trudgett A; Hoey EM; Cromie L; Taylor SM; Daniel R
    Vet Parasitol; 2008 Nov; 157(3-4):222-34. PubMed ID: 18774647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
    Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
    Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of vitellogenesis and spermatogenesis by triclabendazole (TCBZ) in a TCBZ-resistant isolate of Fasciola hepatica following incubation in vitro with a P-glycoprotein inhibitor.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2014 Jul; 141(8):1064-79. PubMed ID: 24889697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of triclabendazole against Fasciola hepatica in sheep and goats.
    Wolff K; Eckert J; Schneiter G; Lutz H
    Vet Parasitol; 1983 Sep; 13(2):145-50. PubMed ID: 6685399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of carboxylesterase activity in Fasciola hepatica recovered from triclabendazole treated sheep.
    Scarcella S; Miranda-Miranda E; Cossío-Bayúgar R; Ceballos L; Fernandez V; Solana H
    Mol Biochem Parasitol; 2012 Oct; 185(2):151-3. PubMed ID: 22814337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-course and accumulation of triclabendazole and its metabolites in bile, liver tissues and flukes collected from treated sheep.
    Moreno L; Ceballos L; Fairweather I; Lanusse C; Alvarez L
    Exp Parasitol; 2014 Jan; 136():14-9. PubMed ID: 24211244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extension of the prepatent period of Fasciola hepatica in infected animals following treatment with triclabendazole.
    Büscher G; Bowen FL; Strong MB; Allison JR; Richards RJ
    Vet Rec; 1987 May; 120(19):460-1. PubMed ID: 3603988
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance of Fasciola hepatica to triclabendazole.
    Overend DJ; Bowen FL
    Aust Vet J; 1995 Jul; 72(7):275-6. PubMed ID: 8534235
    [No Abstract]   [Full Text] [Related]  

  • 18. Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha.
    McConville M; Brennan GP; Flanagan A; Edgar HW; McCoy M; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2008 May; 153(1-2):52-64. PubMed ID: 18359570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica.
    McConville M; Brennan GP; Flanagan A; Edgar HW; Hanna RE; McCoy M; Gordon AW; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2009 May; 162(1-2):75-88. PubMed ID: 19282108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of closantel against adult triclabendazole-resistant Fasciola hepatica.
    Coles GC; Rhodes AC; Stafford KA
    Vet Rec; 2000 Apr; 146(17):504. PubMed ID: 10888001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.